3,5-diphenyl-1H-pyrazin-2-one | 41270-61-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3,5-diphenyl-1H-pyrazin-2-one
• 英文别名: 3,5-Diphenyl-1H-pyrazin-2-on；3,5-Diphenylpyrazin-2(1H)-one；3,5-diphenyl-1H-pyrazin-2-one
• CAS: 41270-61-5
• 化学式: C₁₆H₁₂N₂O
• 分子量: 248.284
• InChiKey: RLBMHWXEJLGHNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,5-diphenyl-1H-pyrazin-2-one 在 三甲基氯硅烷 、 五氯化磷 作用下， 反应 0.5h， 生成 2-chloro-3,5-diphenylpyrazine
  参考文献：
  名称：

  吡嗪的研究。35 †。由羟基吡嗪改进的溴吡嗪合成

  摘要：

  通过三甲基甲硅烷基氧基吡嗪的方法成功地从羟基吡嗪合成了溴吡嗪，其顺序在温和的条件下进行并且不需要分离中间体。

  DOI：

  10.1002/jhet.5570360334
• 作为产物：
  描述：

  1-hydroxy-3,5-diphenyl-1H-pyrazin-2-one 在 乙醇 、 肼 作用下， 生成 3,5-diphenyl-1H-pyrazin-2-one
  参考文献：
  名称：

  Dunn et al., Journal of the Chemical Society, 1949, p. 2707,2710

  摘要：

  DOI：

文献信息

• Methods and compositions for treating alcohol use disorders
  申请人：Sanna Pietro Paolo

  公开号：US10039772B2

  公开（公告）日：2018-08-07

  Disclosed are methods and compositions for treating alcohol dependence by administration to a patient of an inhibitor of 11β-hydroxysteroid dehydrogenases (11β-HSD) to modulate glucocorticoid effects. One such compound is the 11β-HSD inhibitor carbenoxolone (18β-glycyrrhetinic acid 3β-O-hemisuccinate), which has been extensively employed in the clinic for the treatment of gastritis and peptic ulcer. Carbenoxolone is active on both 11β-HSD1 and 2 isoforms. Here, carbenoxolone is surprisingly shown to reduce both baseline and excessive drinking in rats and mice. The carbenoxolone diastereomer 18α-glycyrrhetinic acid 3β-O-hemisuccinate (αCBX), which the applicants discovered to be selective for 11β-HSD2, was also effective in reducing alcohol drinking in mice. Thus, 11β-HSD inhibitors are a new class of candidate alcohol abuse medications and existing 11β-HSD inhibitor drugs may be re-purposed for alcohol abuse treatment.

  本发明公开了通过向患者施用 11β-羟基类固醇脱氢酶（11β-HSD）抑制剂以调节糖皮质激素作用来治疗酒精依赖症的方法和组合物。其中一种化合物是 11β-HSD 抑制剂卡本诺酮（18β-甘草次酸 3β-O-hemisuccinate ），临床上已广泛用于治疗胃炎和消化性溃疡。卡贝诺酮对 11β-HSD1 和 2 同工酶均有活性。令人惊讶的是，羧甲诺龙在大鼠和小鼠体内可减少基线饮酒量和过量饮酒量。申请人发现，羧诺龙的非对映异构体 18α-甘草次酸 3β-O-hemisuccinate (αCBX)对 11β-HSD2 具有选择性，也能有效减少小鼠的饮酒量。因此，11β-HSD 抑制剂是一类新的候选酗酒药物，现有的 11β-HSD 抑制剂药物可重新用于酗酒治疗。
• Age-Associated Accumulation of the Apolipoprotein C-III Gene T-455C Polymorphism C Allele in a Russian Population
  作者：S. V. Anisimov、M. V. Volkova、L. V. Lenskaya、V. K. Khavinson、D. V. Solovieva、E. I. Schwartz

  DOI：10.1093/gerona/56.1.b27

  日期：2001.1.1

  Apolipoprotein C-III (apoC-III) is the major component of triglyceride-rich lipoproteins. One of six identified polymorphisms in the apoC-III 5'-untranslated region (T-455C) is located within a functional insulin-response element. In a group of 137 elderly individuals (70-106 gears old), the allele distribution was analyzed using restriction fragment length polymorphisms. Statistical analysis of allele frequencies was performed on subgroups selected by age and in elderly patients with arterial hypertension or ischemic heart disease. A greater frequency of the apoC-III -455C allele was demonstrated with aging ( p.005). No statistically significant difference in allele distributions was detected between healthy subjects and groups of elderly patients of the same age with either ischemic heart disease or arterial hypertension. The increased incidence of the C allele with advanced age indicates that this variant promoter is associated with longevity. The greater incidence of this allele is detectable only in adults older than 80 years of age.
• Ohta, Akihiro; Imazeki, Akiko; Itoigawa, Yohko, Journal of Heterocyclic Chemistry, 1983, vol. 20, p. 311 - 320
  作者：Ohta, Akihiro、Imazeki, Akiko、Itoigawa, Yohko、Yamada, Hiroko、Suga, Chieko、et al.

  DOI：——

  日期：——
• OHTA, AKIHIRO;IMAZEKI, AKIKO;ITOIGAWA, YOHKO;YAMADA, HIROKO;SUGA, CIEKO;T+, J. HETEROCYCL. CHEM., 1983, 20, N 2, 311-320
  作者：OHTA, AKIHIRO、IMAZEKI, AKIKO、ITOIGAWA, YOHKO、YAMADA, HIROKO、SUGA, CIEKO、T+

  DOI：——

  日期：——
• METHODS AND COMPOSITIONS FOR TREATING ALCOHOL USE DISORDERS
  申请人：SANNA Pietro Paolo

  公开号：US20170232007A1

  公开（公告）日：2017-08-17

  Disclosed are methods and compositions for treating alcohol dependence by administration to a patient of an inhibitor of 11β-hydroxysteroid dehydrogenases (11β-HSD) to modulate glucocorticoid effects. One such compound is the 11β-HSD inhibitor carbenoxolone (18β-glycyrrhetinic acid 3β-O-hemisuccinate), which has been extensively employed in the clinic for the treatment of gastritis and peptic ulcer. Carbenoxolone is active on both 11β-HSD1 and 2 isoforms. Here, carbenoxolone is surprisingly shown to reduce both baseline and excessive drinking in rats and mice. The carbenoxolone diastereomer 18α-glycyrrhetinic acid 3β-O-hemisuccinate (αCBX), which the applicants discovered to be selective for 11β-HSD2, was also effective in reducing alcohol drinking in mice. Thus, 11β-HSD inhibitors are a new class of candidate alcohol abuse medications and existing 11β-HSD inhibitor drugs may be re-purposed for alcohol abuse treatment.